Trials / Completed
CompletedNCT00771329
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB023 | Single IV doses of BIIB023 in dose-escalating cohorts |
| OTHER | Placebo (sterile normal saline) | Single IV dose of Placebo |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2008-10-13
- Last updated
- 2013-09-16
Locations
6 sites across 2 countries: United States, Russia
Source: ClinicalTrials.gov record NCT00771329. Inclusion in this directory is not an endorsement.